Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives

G La Monica, A Bono, A Lauria… - Journal of medicinal …, 2022 - ACS Publications
The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents

A Zagórska, A Czopek, M Fryc, J Jończyk - Biomolecules, 2024 - pmc.ncbi.nlm.nih.gov
The main protease (Mpro) of SARS-CoV-2 is an essential enzyme that plays a critical part in
the virus's life cycle, making it a significant target for develo** antiviral drugs. The …

Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening

G Amendola, R Ettari, S Previti, C Di Chio… - Journal of Chemical …, 2021 - ACS Publications
During almost all 2020, coronavirus disease 2019 (COVID-19) pandemic has constituted the
major risk for the worldwide health and economy, propelling unprecedented efforts to …

Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices

AQK Oyedele, AT Ogunlana, ID Boyenle… - Molecular Diversity, 2023 - Springer
The continuous approval of covalent drugs in recent years for the treatment of diseases has
led to an increased search for covalent agents by medicinal chemists and computational …

Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization

V Di Sarno, G Lauro, S Musella, T Ciaglia… - European Journal of …, 2021 - Elsevier
COVID-19 pandemic, starting from the latest 2019, and caused by SARS-CoV-2 pathogen,
led to the hardest health-socio-economic disaster in the last century. Despite the …

Discovery and characterization of the covalent SARS-CoV-2 3CLpro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical …

YN Zhang, GH Zhu, W Liu, Y **ong, Q Hu, XY Zhuang… - Phytomedicine, 2023 - Elsevier
Background The 3C-like proteases (3CL pro s) are cysteine-rich homodimeric proteins and
can be covalently modified by numerous natural and synthetic compounds, which in turn …

[HTML][HTML] Application of artificial intelligence in COVID-19 medical area: a systematic review

Z Chang, Z Zhan, Z Zhao, Z You, Y Liu… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Background Coronavirus disease 2019 (COVID-19) has caused a large-scale global
epidemic, impacting international politics and the economy. At present, there is no …

Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus

MM Rahman, S Biswas, KJ Islam, AS Paul… - Computers in Biology …, 2021 - Elsevier
Dengue, a mosquito-borne disease, has appeared as a major infectious disease globally.
The virus requires its proteins to replicate and reproduce in the host cell. The NS3 protease …

Recent advances in the design of small molecular drugs with acrylamides covalent warheads

L Liang, Z Zhang, Q You, X Guo - Bioorganic & Medicinal Chemistry, 2024 - Elsevier
In the development of covalent inhibitors, acrylamides warhead is one of the most popular
classes of covalent warheads. In recent years, researchers have made different structural …

Combined Computational NMR and Molecular Docking Scrutiny of Potential Natural SARS-CoV-2 Mpro Inhibitors

VA Semenov, LB Krivdin - The Journal of Physical Chemistry B, 2022 - ACS Publications
In continuation of the search for potential drugs that inhibit the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), in this work, a combined approach based on the …